Search Results - "Uijen, M. J. M."

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports by Uijen, M. J. M., Derks, Y. H. W., Merkx, R. I. J., Schilham, M. G. M., Roosen, J., Privé, B. M., van Lith, S. A. M., van Herpen, C. M. L., Gotthardt, M., Heskamp, S., van Gemert, W. A. M., Nagarajah, J.

“…In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and…”
Get full text

Results of histopathological revisions of major salivary gland neoplasms in routine clinical practice by Reerds, Sam T H, Uijen, Maike J M, Van Engen-Van Grunsven, Adriana C H, Marres, Henri A M, van Herpen, Carla M L, Honings, Jimmie

“…Salivary gland neoplasms are rare and are characterised by overlapping histopathological aspects. Therefore, the assessment of the correct histopathological…”
Get more information

Thoughts on "Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?" by Privé, Bastiaan M, Peters, Steffie MB, Uijen, Maike JM, Janssen, Marcel JR, van Gemert, Willemijn AM, Kreissl, Michael C, Ezzidin, Samer, Konijnenberg, Mark W, Nagarajah, James

Get full text

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study by Banda, Amina, Privé, Bastiaan M, Allach, Youssra, Uijen, Maike J M, Peters, Steffie M B, Loeff, Cato C, Gotthardt, Martin, Muselaers, Constantijn H J, Witjes, J Alfred, van Oort, Inge M, Sedelaar, J P Michiel, Westdorp, Harm, Mehra, Niven, Khreish, Fadi, Ezziddin, Samer, Sabet, Amir, Kreissl, Michael C, Winkens, Thomas, Seifert, Philipp, Janssen, Marcel J R, van Gemert, Willemijn A M, Nagarajah, James

“…Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer…”
Get full text

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review by Uijen, M.J.M., Lassche, G., van Engen-van Grunsven, A.C.H., Tada, Y., Verhaegh, G.W., Schalken, J.A., Driessen, C.M.L., van Herpen, C.M.L.

“…•Salivary duct carcinoma often requires palliative systemic therapy.•Currently no guidelines exist on systemic therapy for this rare cancer.•This paper…”
Get full text

Case Report: Two Cases of Salivary Duct Carcinoma in Workers With a History of Chromate Exposure by Seçin, Imran, Uijen, Maike J M, Driessen, Chantal M L, van Herpen, Carla M L, Scheepers, Paul T J

“…Salivary duct carcinoma (SDC), one subtype of the 22 different salivary gland cancers, is a rare malignancy. Risk factors for the development of salivary gland…”
Get full text

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma by Uijen, M.J.M., Lassche, G., van Engen-van Grunsven, A.C.H., Driessen, C.M.L., van Herpen, C.M.L.

“…•Majority of HER2 + SDC patients responded to first-line HER2 therapy.•Subsequent second-line HER2 therapy also resulted in response in majority of…”
Get full text

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study by Privé, Bastiaan M, Peters, Steffie M B, Muselaers, Constantijn H J, van Oort, Inge M, Janssen, Marcel J R, Sedelaar, J P Michiel, Konijnenberg, Mark W, Zámecnik, Patrik, Uijen, Maike J M, Schilham, Melline G M, Eek, Annemarie, Scheenen, Tom W J, Verzijlbergen, J Fred, Gerritsen, Winald R, Mehra, Niven, Kerkmeijer, Linda G W, Smeenk, Robert J, Somford, Diederik M, van Basten, Jean-Paul A, Heskamp, Sandra, Barentsz, Jelle O, Gotthardt, Martin, Witjes, J Alfred, Nagarajah, James

“…[ Lu]Lu-PSMA-617 radioligand therapy ( Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied…”
Get full text

Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer by Krens, Stefanie D, van Boxtel, Wim, Uijen, Maike J M, Jansman, Frank G A, Desar, Ingrid M E, Mulder, Sasja F, van Herpen, Carla M L, van Erp, Nielka P

“…Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved…”
Get full text

Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry by Uijen, Maike J.M., Privé, Bastiaan M., van Herpen, Carla M.L., Westdorp, Harm, van Gemert, Willemijn A., de Bakker, Maarten, Gotthardt, Martin, Konijnenberg, Mark W., Peters, Steffie M.B., Nagarajah, James

“…For prostate-specific membrane antigen-directed radioligand therapy (PSMA-RLT), [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T are the currently preferred…”
Get full text

Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial by Weijers, Jetty A.M., de Bitter, Tessa J.J., Verhaegh, Gerald W., van Boxtel, Wim, Uijen, Maike J.M., van Engen-van Grunsven, Adriana C.H., Driessen, Chantal M.L., Schalken, Jack A., Ligtenberg, Marjolijn J.L., van Herpen, Carla M.L.

“…•Circulating tumour DNA can be detected in advanced SDC.•Longitudinal ctDNA analysis can be informative to understand disease dynamics in SDC.•ctDNA levels…”
Get full text

Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma by van Boxtel, Wim, Uijen, Maike J.M., Verhaegh, Gerald W., Willems, Stefan M., Jonker, Marianne A., Schalken, Jack A., van Engen-van Grunsven, Ilse C.H., van Herpen, Carla M.L.

“…•c-MET, E-cadherin, and PSMA expression are no independent prognostic factors in SDC.•PSMA tumor expression was higher in women than men.•None of the factors…”
Get full text

Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study by van Ruitenbeek, Niels J, Uijen, Maike J M, Driessen, Chantal M L, Peters, Steffie M B, Privé, Bastiaan M, van Engen-van Grunsven, Adriana C H, Konijnenberg, Mark W, Gotthardt, Martin, Nagarajah, James, van Herpen, Carla M L

“…There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [ Ga]Ga-PSMA-11…”
Get full text

Impact analysis studies of clinical prediction rules relevant to primary care: a systematic review by Wallace, Emma, Uijen, Maike J M, Clyne, Barbara, Zarabzadeh, Atieh, Keogh, Claire, Galvin, Rose, Smith, Susan M, Fahey, Tom

“…ObjectivesFollowing appropriate validation, clinical prediction rules (CPRs) should undergo impact analysis to evaluate their effect on patient care. The aim…”
Get full text

Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer by van Boxtel, Wim, Uijen, Maike J.M., Krens, Stefanie D., Dijkema, Tim, Willems, Stefan M., Jonker, Marianne A., Pegge, Sjoert A.H., van Engen-van Grunsven, Adriana C.H., van Herpen, Carla M.L.

“…Because the tyrosine kinases c-MET and vascular endothelial growth factor receptors (VEGFR) are often overexpressed in salivary gland cancer (SGC), this study…”
Get full text

Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer by Driessen, Chantal M. L., Uijen, Maike J. M., van der Graaf, Winette T. A., van Opstal, Claudia C. M., Kaanders, Johannes H. A. M., Nijenhuis, Tom, van Herpen, Carla M. L.

“…Background The purpose of this study was to compare the occurrence of cisplatin‐induced nephrotoxicity between concomitant chemoradiotherapy with high versus…”
Get full text

Cutaneous lymphangitis carcinomatosa in salivary duct carcinoma by Uijen, Maike Jm, Weijers, Jetty Am, Lassche, Gerben, van Ravensteijn, Stefan G, van Rijk, Maartje C, Lubeek, Satish Fk, van Engen-van Grunsven, Adriana Ch, Amir, Avital, Driessen, Chantal Ml, van Herpen, Carla Ml

Get more information

Performance of Modulation Codes in Various Optical Recording Media by C. M. J. van Uijen, C. M. J. van Uijen, J. H. M. Spruit, J. H. M. Spruit

“…The performance of modulation codes has been measured in ablative and magneto-optic recording media as well as in mastered direct discs. The modulation codes…”
Get full text

An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer by Privé, Bastiaan M., Muselaers, Constantijn H. J., van Oort, Inge M., Janssen, Marcel J. R., Peters, Steffie M. B., van Gemert, Willemijn A. M., Uijen, Maike J. M., Schilham, Melline M. G., Sedelaar, J. P. Michiel, Westdorp, Harm, Mehra, Niven, Gotthardt, Martin, Barentsz, Jelle O., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James

“…177 Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate…”
Get full text

Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma by Tasche, M J, van der Wouden, J C, Uijen, J H, Ponsioen, B P, Bernsen, R M, van Suijlekom-Smit, L W, de Jongste, J C

“…Inhalation therapy with sodium cromoglycate is recommended as the first-line prophylactic treatment for moderate asthma in children. The availability of spacer…”
Get more information